RxDoctor Payments Data

Hua Lin

Gerontology · Birmingham, ALNPI 1073068516

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 21 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,026 and has fallen 72.3% since, to $284 in 2025.

$2,046in general payments, 2019–2025

Across 21 payments — averaging $97.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axsome Therapeutics, Inc.$372
  • AbbVie$243
  • Teva Pharmaceuticals USA, Inc.$229
  • Scpharmaceuticals Inc.$220
  • Neurocrine Biosciences, Inc.$127
  • Sumitomo Pharma America, Inc.$125
  • plus $728 from 8 others

What the payments were for

  • Food & beverage$2,046100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,046 in reported general payments places this provider in the 75th percentile of 143 gerontology providers in Alabama.

See all gerontology providers in Alabama

Medicare billing

Part B allowed, 2024
$67,421
Medicare patients
226
Services billed
944

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban94$69,743
TrulicityDulaglutide23$21,296
JanuviaSitagliptin Phosphate28$21,101
JardianceEmpagliflozin15$19,335
Breo ElliptaFluticasone/Vilanterol11$4,326
Rivastigmine15$3,856
Metformin Hcl49$2,291
Levothyroxine Sodium121$1,870
Atorvastatin Calcium132$1,771
Albuterol Sulfate HfaAlbuterol Sulfate53$1,370
Amlodipine Besylate150$1,312
Donepezil Hcl74$1,271
Duloxetine Hcl29$1,094
Mirtazapine38$1,092
Pravastatin Sodium39$1,025

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$15$21,29623 claims
MerckJanuvia$114$21,10128 claims
GSKBreo Ellipta$31$4,32611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 143 gerontology providers in Alabama.

Other gerontology in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →